Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 50 | Millennium Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Feb 24, 2023 |
| clinicaltrials |
| NCT05571787 | HMPL-523 Food Effect and Proton Pump Inhibitor Study | completed | Phase 1 | 26 | HutchmedINDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02278315 | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 31 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT01756118 | A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 24 | Goethe UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | completed | Phase 1 | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03836768 | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | completed | Phase 1 | 20 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04626843 | Intermittent Fasting and CLL/SLL | completed | Phase 1 | 15 | Eleah StringerOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT01768338 | Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma | completed | Phase 1 | 9 | Michael John RobertsonOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02257242 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma(BRiM) | completed | Phase 1 | 11 | Brown UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT00585195 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001) | completed | Phase 1 | 596 | PfizerINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03357627 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT04152148 | A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients | completed | Phase 1 | 16 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT00806065 | Study of ENMD-2076 in Patients With Multiple Myeloma | completed | Phase 1 | 13 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02658929 | Study of bb2121 in Multiple Myeloma | completed | Phase 1 | 67 | CelgeneINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02342665 | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | completed | Phase 1 / Phase 2 | 25 | BayerINDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03049449 | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03454165 | A Study of BNC105P Combined With Ibrutinib | completed | Phase 1 | 6 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT04185220 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT00664898 | A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03809767 | A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 107 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05563545 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 2 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 331 | Hoffmann-La RocheINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT03009344 | A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02572167 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 93 | Seagen Inc.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01575925 | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)(POM Renal) | completed | Phase 1 | 25 | CelgeneINDUSTRY | 2 | Nov 4, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03019666 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | completed | Phase 1 | 39 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03770000 | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | completed | Phase 1 / Phase 2 | 33 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT01380145 | MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | completed | Phase 1 | 13 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02535286 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | completed | Phase 1 | 27 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | completed | Phase 1 | 6 | Julio Barredo, MDOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02756247 | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | completed | Phase 1 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | completed | Phase 1 / Phase 2 | 28 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT01886859 | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2023source: clinicaltrials